Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring

doi:10.3748/wjg.v27.i37.6231

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 37

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7036)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

483

WORD

154

HTML

4476

Figures (1-1)

367

Tables (1-4)

542

Sum=6022

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

376

Download

638

Sum=1014

Oct 7, 2021 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Oct 7, 2021; 27(37): 6231-6247
Published online Oct 7, 2021. doi: 10.3748/wjg.v27.i37.6231

Open in New Tab Full Size Figure Download Figure

Figure 1 Therapeutic drug monitoring based approach to treatment failure. IBD: Inflammatory bowel disease; ADA: Anti-drug antibody.

Citation: Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247
URL: https://www.wjgnet.com/1007-9327/full/v27/i37/6231.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i37.6231